SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today the addition of Mr. Jordan Wittmeier as Director of International MicroThermX® Sales. Mr. Wittmeier’s appointment will increase resourcing of BSD’s international market launch of the MicroThermX® Microwave Ablation (MicroThermX®) product line. Mr. Wittmeier has over 27 years of experience in the medical device industry, including new product launches, domestic and international sales and distribution management, implementation strategies, and strategic partnering.
Mr. Wittmeier has been instrumental in successfully launching a number of new disposable medical devices and capital equipment product lines throughout the world. Mr. Wittmeier will provide sales and marketing management and support for the planned expansion of the MicroThermX® international distribution network the Company is bringing on line to capitalize on the large opportunity in the ablation market.
“With our United States sales and distribution network in place for our MicroThermX® family of products,” said Harold Wolcott, BSD’s President, “we will be placing significant emphasis on Europe and other international markets. Jordan will be a strong contributor to our worldwide business success.”
About the MicroThermX® Microwave Ablation System
The MicroThermX® Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® system in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.